

## Special Issue

# Smoking Cessation after a Cancer Diagnosis

### Message from the Guest Editors

Achieving the best outcomes for cancer patients requires the delivery of sophisticated surgery, high-precision radiotherapy and an ever-expanding variety of systemic therapies often administered in combination. However, for each of these therapies to achieve their maximum benefit with the least possible toxicity, cancer patients who smoke will need help in quitting. Furthermore, advances in these therapies have led to a growing population of cancer survivors, including patients with metastatic disease, who would derive many non-cancer-related (e.g., cardiorespiratory) benefits if they quit smoking. There is still much to be learned about the interactions between tobacco smoke and the cancer therapies used by oncologists, particularly systemic therapies. This Special Issue will focus on what is currently known about the impact of smoking on each of the key cancer treatment modalities and underscore the need for more research on how continued smoking impacts the effectiveness of the different classes of new agents.

---

### Guest Editors

Prof. emer. William K. Evans

Dr. Meredith Giuliani

Dr. Lawson Eng

---

### Deadline for manuscript submissions

closed (15 February 2022)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/si/80762](https://mdpi.com/si/80762)

*Current Oncology*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
curroncol](https://mdpi.com/journal/curroncol)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/journal/  
currenocol](https://mdpi.com/journal/currenocol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
  2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
- 

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility

: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)